| Summary: | As antimicrobial resistance continues to be an issue across health care settings, guidelines for appropriate practices related to antibiotic prescribing and use are required. The prevalence of resistant pathogens has also encouraged the development of new treatment options to effectively combat them. One recently developed antimicrobia l therapy is the fixed-dose combination of ceftolozane (a novel cephalosporin) and tazobactam (a beta-lactamase inhibitor), marketed as Zerbaxa. It is provided as a lyophilized powder in a 1.5 g dose (1 g ceftolozane and 500 mg tazobactam) per vial for intravenous (IV) administration. IV ceftolozane/tazobactam is indicated for the treatment of complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI), including pyelonephritis, caused by susceptible, primarily Gram-negative bacterial strains. Health Canada issued a Notice of Compliance for Zerbaxa in September 2015 and the date of first sale was in January 2016. Given the recent introduction of IV ceftolozane/tazobactam into clinical practice, evidence is required to support its broader use and to better understand its place in therapy relative to existing antimicrobial treatment options. The purpose of this report is to evaluate the clinical effectiveness, cost-effectiveness, and evidence-based guidelines for the use of ceftolozane/tazobactam for patients with bacterial infections
|
|---|